BC Innovations | May 16, 2018
Distillery Therapeutics

Infectious disease

INDICATION: Respiratory syncytial virus (RSV); viral infection Patient sample and mouse studies suggest inhibiting PTGDR2 or agonizing PTGDR1 could help treat RSV and other viral infections. In nasal secretions from respiratory syncytial virus (RSV)-infected infants...
BC Innovations | Aug 28, 2014
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Amyotrophic lateral sclerosis (ALS) Prostaglandin D2 receptor subtype DP1 (PTGDR1; DP1); superoxide dismutase 1 (SOD1) Cell culture and mouse studies suggest inhibiting DP1 could help...
BC Innovations | Aug 28, 2014
Targets & Mechanisms

A cultured approach to ALS therapy

Although dysfunctional glial cells have long been implicated in amyotrophic lateral sclerosis progression, the precise mechanisms by which they contribute to the disease have remained poorly defined. Now, Harvard University researchers have identified a specific...
BC Week In Review | Dec 9, 2013
Clinical News

OC459: Phase II started

Atopix began a double-blind, placebo-controlled, European Phase II trial to evaluate once-daily oral OC459 for 6 months. The trial is funded by an £1.7 million ($2.8 million) grant from the U.K. Biomedical Catalyst fund (see...
BC Week In Review | Jul 29, 2013
Clinical News

ARRY-502: Phase II data

A double-blind, U.S. Phase II trial in 184 patients with mild to moderate persistent allergic asthma showed that twice-daily 200 mg oral ARRY-502 for 4 weeks met the primary endpoint of improving pre-bronchodilator FEV1 from...
BC Week In Review | Jun 3, 2013
Company News

Atopix Therapeutics, Medical Research Council, U.K. Technology Strategy Board (TSB) dermatology news

In April, Atopix received a £1.7 million ($2.6 million) award from the U.K. Biomedical Catalyst fund to develop the company's lead compound, OC459 , to treat moderate-to-severe atopic dermatitis. The product has completed Phase I testing...
BC Week In Review | Mar 18, 2013
Clinical News

Tredaptive: Additional Phase III data

Additional data from the investigator-led, double-blind, placebo-controlled, European and Chinese Phase III HPS2-THRIVE trial in 25,673 patients at high risk for cardiovascular events showed that the primary composite endpoint of coronary death, non-fatal MI, stroke...
BC Week In Review | Feb 11, 2013
Clinical News

S-555739: Phase III started

Shionogi disclosed in its 3Q12 earnings for the period ending Dec. 31, 2012, that it began a double-blind, Japanese Phase III trial evaluating oral S-555739 in patients with Japanese cedar pollinosis. Shionogi & Co. Ltd....
BC Week In Review | Jan 28, 2013
Clinical News

Tredaptive regulatory update

EMA's CHMP confirmed a recommendation from the agency's Pharmacovigilance Risk Assessment Committee to suspend marketing authorization of Tredaptive in the EU. EMA began a review of the drug in December after data from the investigator-led...
BC Week In Review | Jan 14, 2013
Clinical News

Tredaptive regulatory update

Merck said it will suspend the worldwide availability of Tredaptive after data from the investigator-led Phase III HPS2-THRIVE trial showed the cardiovascular drug plus statin therapy failed to reduce the incidence of cardiovascular events and...
Items per page:
1 - 10 of 42